Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Ibrutinib Plus Rituximab Shows PFS Benefit Over Chemoimmunotherapy in Untreated MCL

October 10th 2025

Ibrutinib plus rituximab showed a progression-free survival benefit vs standard chemoimmunotherapy in older patients with untreated mantle cell lymphoma.

Dr Dreyling on the Rationale for Adding Acalabrutinib to BR in High-Risk MCL

October 8th 2025

Martin Dreyling, MD, discusses why adding acalabrutinib to bendamustine plus rituximab may benefit patients with pretreated, high-risk MCL.

Dr Saad on the Rationale for the PEACE-3 Trial in mCRPC With Bone-Predominant Disease

October 8th 2025

Fred Saad, MD, discusses the rationale behind the long-term safety analysis for radium-223 dichloride and enzalutamide in metastatic castration-resistant prostate cancer with bone-predominant disease.

OncLive Poll Results Spotlight Highly Anticipated Hematology Topics Ahead of ESMO 2025

October 3rd 2025

Multiple myeloma and non-Hodgkin lymphoma emerge as key hematology topics ahead of ESMO 2025, followed by MPNs and T-cell lymphoma.

Dr Yuan on Intracranial Activity With T-DXd Plus Pertuzumab in HER2+ Metastatic Breast Cancer

October 3rd 2025

Yuan Yuan, MD, PhD, reports the intracranial efficacy of T-DXd plus pertuzumab in HER2-positive breast cancer, per results from the DESTINY-Breast12 study.

Dr Martini on the Mechanism of Action of Cretostimogene Grenadenorepvec in Urothelial Carcinoma

October 3rd 2025

Alberto Martini, MD, discusses cretostimogene grenadenorepvec in urothelial carcinoma.

Dr LeVee on T-DXd in HER2+ Breast Cancer With/Without Brain Metastases

October 3rd 2025

Alexis LeVee, MD, discusses T-DXd in HER2+ breast cancer with or without brain metastases.

Dr Arora on the Declining Incidence of MCL in the United States

October 2nd 2025

Ruby Arora, MD, discusses the declining incidence of MCL in the US, as well as ways to address disparities that remain in MCL management.

Dr LeVee on Selecting and Sequencing ADCs in Breast Cancer

October 2nd 2025

Alexis LeVee, MD, discusses how clinical trial design guides the practical application of data for ADC selection in breast cancer.

Dr Sweis on Targeting ENPP3 in Clear Cell Renal Cell Carcinoma

October 2nd 2025

Randy F. Sweis, MD, discusses the potential utility of ENPP3 as a therapeutic target in RCC.

OncLive’s September EMA Regulatory Recap: Key EU Approvals in Oncology

October 2nd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

Is AI Augmentation Driving Smarter, Better Cancer Care?

October 2nd 2025

Four experts share their perspectives on the potential challenges and future directions for AI integration in the field of oncology.

Dr Dahiya on the Unique Mechanism of Action of KITE-363 in LBCL

October 1st 2025

Saurabh Dahiya, MD, FACP, discusses the unique mechanism of action of the CD19/CD20–targeting CAR T-cell therapy in relapsed/refractory LBCL.

Dr Khan on the Evolution of BTK Inhibitors in CLL

October 1st 2025

Cyrus M. Khan, MD, discusses how ibrutinib—a first-generation BTK inhibitor—compares with second-generation BTK inhibitors in CLL.

FDA Grants Fast Track Designation to ETX-636 for PIK3CA-Mutant, HR+/HER2-Negative Breast Cancer

October 1st 2025

ETX-636, a selective PI3Kα inhibitor, has received FDA fast track designation for PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer.

FDA Accepts sBLA for T-DXd Followed by THP in High-Risk, HER2+ Early-Stage Breast Cancer

October 1st 2025

The FDA accepted an sBLA seeking the approval of neoadjuvant T-DXd followed by THP for the management of high-risk, HER2-positive breast cancer.

Dr Yuan on T-DXd in First-Line HER2+ Advanced/Metastatic Breast Cancer

September 30th 2025

Yuan Yuan, MD, PhD, discusses T-DXd plus pertuzumab in first-line HER2-positive advanced/metastatic breast cancer.

Dr Koo on Results From a Survey on Barriers to Prostate Cancer Screening

September 30th 2025

Phillip Koo, MD, discusses findings from a survey of prostate cancer screening rates.

Dr Gellhaus on the Advantages and Limitations of Focal Therapy for Prostate Cancer

September 30th 2025

Paul Gellhaus, MD, discusses ongoing developments with focal therapy in prostate cancer and potential avenues for technological improvement.

Dr Dietrich on the Limitations of Chemotherapy in Pancreatic Cancer

September 30th 2025

Martin F. Dietrich, MD, PhD, discusses the limitations of frontline chemotherapy in advanced/metastatic pancreatic cancer.